IMVAMUNE®

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Feb 1, 2013 → Jun 1, 2014

About IMVAMUNE®

IMVAMUNE® is a phase 3 stage product being developed by Bavarian Nordic for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT01144637. Target conditions include Smallpox.

What happened to similar drugs?

3 of 7 similar drugs in Smallpox were approved

Approved (3) Terminated (0) Active (4)
🔄FD MVA-BNBavarian NordicPhase 3
🔄ACAM2000Emergent BioSolutionsPhase 3
Vaccination with ACAM2000Emergent BioSolutionsApproved
🔄tecovirimatSIGA TechnologiesPhase 3
🔄TPOXXSIGA TechnologiesPhase 3
TpoxxSIGA TechnologiesApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02038881Phase 2Completed
NCT01144637Phase 3Completed
NCT03472014ApprovedCompleted

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
35
MVA (smallpox vaccine)SanofiPhase 1
21
ACAM3000 MVA VaccineSanofiPhase 1
29
MVA Smallpox vaccine + PlaceboSanofiPhase 2
35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
27
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
32
MVA-BNBavarian NordicPhase 1
26
IMVAMUNE®Bavarian NordicPhase 2
32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
32
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
FD MVA-BNBavarian NordicPhase 3
37
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
32
Elstree-BNBavarian NordicPhase 1
26
ACAM2000Emergent BioSolutionsPhase 3
30
VIGIVEmergent BioSolutionsPre-clinical
23
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
16
BrincidofovirEmergent BioSolutionsPhase 1
19
Vaccination with ACAM2000Emergent BioSolutionsApproved
33